Frank: I am curious as to how you found this Lovaza off-label usage. Is there a publication or website that keep tracks of these sales?
What do you think about Niaspan? Is it also in the same trig space with Lovaza and Vascepa and should be impacted by Vascepa's ANCHOR decision as well?
One thing to worry is doctors will not prescribe until there is proven cv outcomes benefit.
We will need to wait for reduceit conclusions before real prescriptions would start. I tell you, if reduceit can demonstrate actual health benefit to lowering triglycerides, epa will be selling like mad.
"Getting rich overnight" is not realistic. Anchor may carry the PPS to a higher level. But the build-up of its full value may need three or four years from now (except a BO). And risks still be there. However, Anchor in October is a very significant milestone to AMRN. I doubled my position last week, may trade some in October, and hold the rest passing thro Reduce-It.
So Lovaza is around 90k a week in scrips ....so about 60K of that should go to Vascepa if you are correct.....and the time frame for that to happen ..6 months into 2014 ?...and based on Insurance challenging the MD's that currently prescribe Lovaza off label.
I just think that unfortunately it all happens a lot slower then most think ...and don't mind if I'm wrong and discover its happening a lot faster then expected.